I-mab

Phillip Andrew Dennis, Chief Medical Officer of I-Mab, sold 8,209 shares of common stock on September 17, 2026 for $0.71 per share.

Sean Wuxiong Cao, Chief Bus. Development Officer of I-Mab, sold 107,978 shares of common stock on September 9, 2026 for $0.74 per share.

Sean Wuxiong Cao, Chief Bus. Development Officer of I-Mab, reported multiple transactions in common stock on September 3, 2026.

Cong Claire Xu, EVP, Clinical Development of I-Mab, sold 3,282 shares of common stock on August 30, 2026 for $0.79 per share.

Robert A. Lenz, a Director of I-Mab, reported multiple transactions in common stock on August 22, 2026.

Mark Hagler, Chief Commercial Officer of NovaBridge Biosciences, received a significant stock option grant on July 8, 2026, as detailed in a Form 4 filing.

An amendment to Schedule 13D reveals updated beneficial ownership percentages in NovaBridge Biosciences by Wei Fu and affiliated C-Bridge entities, with Mr. Fu holding 11.5%.

An amendment to Schedule 13D clarifies beneficial ownership of I-MAB shares by CBC Group entities and Wei Fu, explicitly disclaiming a 'group' with Everest Medicines Limited.

Everest Medicines Limited has acquired a significant stake in I-MAB, increasing its beneficial ownership to 16.1% through a recent underwritten offering.

A group of investment entities and individuals, led by Wei Fu, has significantly increased their beneficial ownership in I-MAB, triggering a Schedule 13D filing with the SEC.